Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Over 300 international researchers from the Observational Health Data Sciences and Informatics (OHDSI) community studied data from almost 1 million patients. They declared hydroxychloroquine safe for short-term use, but urge caution in using it in combination with azithromycin.

The largest analysis to date on the safety of the drug hydroxychloroquine, found there were no worrying side effects

In the face of the rapid spread and escalation of the coronavirus, many decisions are being made quickly and a number of therapies are being trialled for its treatment. One of these is the use of hydroxychloroquine, a drug approved in 1950's for the treatment of malaria, lupus and rheumatoid arthritis.

In the last few days in the USA the FDA has approved the use of hydroxychloroquine for compassionate use in the treatment of COVID-19. Despite the lack of evidence of its clinical effectiveness, President Donald Trump says the drug has shown 'very encouraging results' in treating coronavirus.

Led by Prof Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at the Centre for Statistics in Medicine (NDORMS), a team of researchers from around the world set out to analyse the safety profile of hydroxychloroquine.

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) website

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.